Skip to main content
Top

16-05-2024 | Thyroid Cancer | Original Article

Prediction of TNFRSF9 expression and molecular pathological features in thyroid cancer using machine learning to construct Pathomics models

Authors: Ying Liu, Junping Zhang, Shanshan Li, Wen Chen, Rongqian Wu, Zejin Hao, Jixiong Xu

Published in: Endocrine

Login to get access

Abstract

Background

The TNFRSF9 molecule is pivotal in thyroid carcinoma (THCA) development. This study utilizes Pathomics techniques to predict TNFRSF9 expression in THCA tissue and explore its molecular mechanisms.

Methods

Transcriptome data, pathology images, and clinical information from the cancer genome atlas (TCGA) were analyzed. Image segmentation and feature extraction were performed using the OTSU’s algorithm and pyradiomics package. The dataset was split for training and validation. Features were selected using maximum relevance minimum redundancy recursive feature elimination (mRMR_RFE) and modeling conducted with the gradient boosting machine (GBM) algorithm. Model evaluation included receiver operating characteristic curve (ROC) analysis. The Pathomics model output a probabilistic pathomics score (PS) for gene expression prediction, with its prognostic value assessed in TNFRSF9 expression groups. Subsequent analysis involved gene set variation analysis (GSVA), immune gene expression, cell abundance, immunotherapy susceptibility, and gene mutation analysis.

Results

High TNFRSF9 expression correlated with worsened progression-free interval (PFI) and acted as an independent risk factor [hazard ratio (HR) = 2.178, 95% confidence interval (CI) 1.045–4.538, P = 0.038]. Nine pathohistological features were identified. The GBM Pathomics model demonstrated good prediction efficacy [area under the curve (AUC) 0.819 and 0.769] and clinical benefits. High PS was a PFI risk factor (HR = 2.156, 95% CI 1.047–4.440, P = 0.037). Patients with high PS potentially exhibited enriched pathways, increased TIGIT gene expression, Tregs infiltration (P < 0.0001), and higher rates of gene mutations (BRAF, TTN, TG).

Conclusions

The GBM Pathomics model constructed based on the pathohistological features of H&E-stained sections well predicted the expression level of TNFRSF9 molecules in THCA.
Appendix
Available only for authorised users
Literature
1.
go back to reference F. Bray, J. Ferlay, I. Soerjomataram et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018)CrossRefPubMed F. Bray, J. Ferlay, I. Soerjomataram et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018)CrossRefPubMed
2.
go back to reference S. Vaccarella, S. Franceschi, F. Bray et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N. Engl. J. Med. 375(7), 614–617 (2016)CrossRefPubMed S. Vaccarella, S. Franceschi, F. Bray et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N. Engl. J. Med. 375(7), 614–617 (2016)CrossRefPubMed
3.
4.
go back to reference M. Pizzato, M. Li, J. Vignat et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 10(4), 264–272 (2022)CrossRefPubMed M. Pizzato, M. Li, J. Vignat et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 10(4), 264–272 (2022)CrossRefPubMed
5.
6.
go back to reference Y.K. Lee, N. Hong, S.H. Park et al. The relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma. Sci. Rep. 9(1), 11435 (2019)CrossRefPubMedPubMedCentral Y.K. Lee, N. Hong, S.H. Park et al. The relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma. Sci. Rep. 9(1), 11435 (2019)CrossRefPubMedPubMedCentral
7.
go back to reference X. Han, J. Chen, J. Wang et al. TTN mutations predict a poor prognosis in patients with thyroid cancer. Biosci. Rep. 42(7), BSR20221168 (2022) X. Han, J. Chen, J. Wang et al. TTN mutations predict a poor prognosis in patients with thyroid cancer. Biosci. Rep. 42(7), BSR20221168 (2022)
8.
go back to reference G. Vitale, G. Pellegrino, E. Desiderio et al. Radioiodine-refractory thyroid cancer: a complex challenge. Minerva Med. 112(6), 686–688 (2021)PubMed G. Vitale, G. Pellegrino, E. Desiderio et al. Radioiodine-refractory thyroid cancer: a complex challenge. Minerva Med. 112(6), 686–688 (2021)PubMed
9.
go back to reference R. Pang, C. Qin, Development of a risk predictive model for evaluating immune infiltration status in invasive thyroid Carcinoma. Evid. Based Complement. Altern. Med. 2022, 5803077 (2022)CrossRef R. Pang, C. Qin, Development of a risk predictive model for evaluating immune infiltration status in invasive thyroid Carcinoma. Evid. Based Complement. Altern. Med. 2022, 5803077 (2022)CrossRef
10.
go back to reference A. Fröhlich, S. Loick, E.G. Bawden et al. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. EBioMedicine. 52, 102647 (2020)CrossRefPubMedPubMedCentral A. Fröhlich, S. Loick, E.G. Bawden et al. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. EBioMedicine. 52, 102647 (2020)CrossRefPubMedPubMedCentral
11.
go back to reference C. Wang, G.H. Lin, A.J. McPherson et al. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol. Rev. 229(1), 192–215 (2009)CrossRefPubMed C. Wang, G.H. Lin, A.J. McPherson et al. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol. Rev. 229(1), 192–215 (2009)CrossRefPubMed
12.
go back to reference S.W. Lee, A.T. Vella, B.S. Kwon et al. Enhanced CD4 T cell responsiveness in the absence of 4-1BB. J. Immunol. 174(11), 6803–6808 (2005)CrossRefPubMed S.W. Lee, A.T. Vella, B.S. Kwon et al. Enhanced CD4 T cell responsiveness in the absence of 4-1BB. J. Immunol. 174(11), 6803–6808 (2005)CrossRefPubMed
13.
go back to reference W.T. Ho, W.L. Pang, S.M. Chong et al. Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression. Cancer Res. 73(2), 652–661 (2013)CrossRefPubMed W.T. Ho, W.L. Pang, S.M. Chong et al. Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression. Cancer Res. 73(2), 652–661 (2013)CrossRefPubMed
14.
go back to reference J. Wu, Y. Wang, Y. Yang et al. TNFSF9 promotes metastasis of pancreatic cancer by regulating M2 polarization of macrophages through Src/FAK/p-Akt/IL-1β signaling. Int. Immunopharmacol. 102, 108429 (2022)CrossRefPubMed J. Wu, Y. Wang, Y. Yang et al. TNFSF9 promotes metastasis of pancreatic cancer by regulating M2 polarization of macrophages through Src/FAK/p-Akt/IL-1β signaling. Int. Immunopharmacol. 102, 108429 (2022)CrossRefPubMed
15.
go back to reference V.G. Bhoj, L. Li, K. Parvathaneni et al. Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4. Mol. Ther. Oncolytics 20, 387–398 (2021)CrossRefPubMedPubMedCentral V.G. Bhoj, L. Li, K. Parvathaneni et al. Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4. Mol. Ther. Oncolytics 20, 387–398 (2021)CrossRefPubMedPubMedCentral
16.
go back to reference B.C. Bertol, E.S. Bales, J.D. Calhoun et al. Lenvatinib plus Anti-PD-1 combination therapy for advanced cancers: defining mechanisms of resistance in an inducible transgenic model of thyroid cancer. Thyroid. 32(2), 153–163 (2022)CrossRefPubMedPubMedCentral B.C. Bertol, E.S. Bales, J.D. Calhoun et al. Lenvatinib plus Anti-PD-1 combination therapy for advanced cancers: defining mechanisms of resistance in an inducible transgenic model of thyroid cancer. Thyroid. 32(2), 153–163 (2022)CrossRefPubMedPubMedCentral
17.
go back to reference K. Liu, J. Hu, Classification of acute myeloid leukemia M1 and M2 subtypes using machine learning. Comput. Biol. Med. 147, 105741 (2022)CrossRefPubMed K. Liu, J. Hu, Classification of acute myeloid leukemia M1 and M2 subtypes using machine learning. Comput. Biol. Med. 147, 105741 (2022)CrossRefPubMed
18.
go back to reference M. Nishio, M. Nishio, N. Jimbo et al. Homology-based image processing for automatic classification of histopathological images of lung tissue. Cancers. 13(6), 1192 (2021) M. Nishio, M. Nishio, N. Jimbo et al. Homology-based image processing for automatic classification of histopathological images of lung tissue. Cancers. 13(6), 1192 (2021)
19.
go back to reference G.L. Banna, T. Olivier, F. Rundo et al. The promise of digital biopsy for the prediction of tumor molecular features and clinical outcomes associated with immunotherapy. Front. Med. 6, 172 (2019)CrossRef G.L. Banna, T. Olivier, F. Rundo et al. The promise of digital biopsy for the prediction of tumor molecular features and clinical outcomes associated with immunotherapy. Front. Med. 6, 172 (2019)CrossRef
20.
go back to reference J. Xie, L. Chen, Q. Tang et al. A necroptosis-related prognostic model of uveal melanoma was constructed by single-cell sequencing analysis and weighted co-expression network analysis based on public databases. Front. Immunol. 13, 847624 (2022)CrossRefPubMedPubMedCentral J. Xie, L. Chen, Q. Tang et al. A necroptosis-related prognostic model of uveal melanoma was constructed by single-cell sequencing analysis and weighted co-expression network analysis based on public databases. Front. Immunol. 13, 847624 (2022)CrossRefPubMedPubMedCentral
21.
go back to reference S. Zhang, S. Chen, Y. Wang et al. Association of a novel prognosis model with tumor mutation burden and tumor-infiltrating immune cells in thyroid carcinoma. Front. Genet. 12, 744304 (2021)CrossRefPubMedPubMedCentral S. Zhang, S. Chen, Y. Wang et al. Association of a novel prognosis model with tumor mutation burden and tumor-infiltrating immune cells in thyroid carcinoma. Front. Genet. 12, 744304 (2021)CrossRefPubMedPubMedCentral
22.
go back to reference Y. Qin, D. Zhang, H. Zhang et al. Construction of a ferroptosis-related five-lncRNA signature for predicting prognosis and immune response in thyroid carcinoma. Cancer Cell Int. 22(1), 296 (2022)CrossRefPubMedPubMedCentral Y. Qin, D. Zhang, H. Zhang et al. Construction of a ferroptosis-related five-lncRNA signature for predicting prognosis and immune response in thyroid carcinoma. Cancer Cell Int. 22(1), 296 (2022)CrossRefPubMedPubMedCentral
23.
go back to reference Y. Zhu, T. Yu, J. Huang et al. Development and validation of prognostic m6A-related lncRNA and mRNA model in thyroid cancer. Am. J. Cancer Res. 12(7), 3259–3279 (2022)PubMedPubMedCentral Y. Zhu, T. Yu, J. Huang et al. Development and validation of prognostic m6A-related lncRNA and mRNA model in thyroid cancer. Am. J. Cancer Res. 12(7), 3259–3279 (2022)PubMedPubMedCentral
24.
go back to reference L. Chang, Y. Zhang, J. Zhu et al. An integrated nomogram combining deep learning, clinical characteristics and ultrasound features for predicting central lymph node metastasis in papillary thyroid cancer: a multicenter study. Front. Endocrinol. 14, 964074 (2023)CrossRef L. Chang, Y. Zhang, J. Zhu et al. An integrated nomogram combining deep learning, clinical characteristics and ultrasound features for predicting central lymph node metastasis in papillary thyroid cancer: a multicenter study. Front. Endocrinol. 14, 964074 (2023)CrossRef
25.
go back to reference S. Peng, Y. Liu, W. Lv et al. Deep learning-based artificial intelligence model to assist thyroid nodule diagnosis and management: a multicentre diagnostic study. Lancet Digit Health 3(4), e250–e259 (2021)CrossRefPubMed S. Peng, Y. Liu, W. Lv et al. Deep learning-based artificial intelligence model to assist thyroid nodule diagnosis and management: a multicentre diagnostic study. Lancet Digit Health 3(4), e250–e259 (2021)CrossRefPubMed
26.
go back to reference Q. Qi, X. Huang, Y. Zhang et al. Ultrasound image-based deep learning to assist in diagnosing gross extrathyroidal extension thyroid cancer: a retrospective multicenter study. EClinicalMedicine 58, 101905 (2023)CrossRefPubMedPubMedCentral Q. Qi, X. Huang, Y. Zhang et al. Ultrasound image-based deep learning to assist in diagnosing gross extrathyroidal extension thyroid cancer: a retrospective multicenter study. EClinicalMedicine 58, 101905 (2023)CrossRefPubMedPubMedCentral
27.
go back to reference F. Li, D. Pan, Y. He et al. Using ultrasound features and radiomics analysis to predict lymph node metastasis in patients with thyroid cancer. BMC Surg. 20(1), 315 (2020)CrossRefPubMedPubMedCentral F. Li, D. Pan, Y. He et al. Using ultrasound features and radiomics analysis to predict lymph node metastasis in patients with thyroid cancer. BMC Surg. 20(1), 315 (2020)CrossRefPubMedPubMedCentral
28.
go back to reference W. He, Y. Sun, J. Ge et al. STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma. Front. Endocrinol. 14, 1076640 (2023)CrossRef W. He, Y. Sun, J. Ge et al. STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma. Front. Endocrinol. 14, 1076640 (2023)CrossRef
29.
go back to reference X. Zhu, C. Chen, Q. Guo et al. Deep learning-based recognition of different thyroid cancer categories using whole frozen-slide images. Front. Bioeng. Biotechnol. 10, 857377 (2022)CrossRefPubMedPubMedCentral X. Zhu, C. Chen, Q. Guo et al. Deep learning-based recognition of different thyroid cancer categories using whole frozen-slide images. Front. Bioeng. Biotechnol. 10, 857377 (2022)CrossRefPubMedPubMedCentral
31.
go back to reference K. Ikegami, S. Refetoff, E. Van Cauter et al. Interconnection between circadian clocks and thyroid function. Nat. Rev. Endocrinol. 15(10), 590–600 (2019)CrossRefPubMedPubMedCentral K. Ikegami, S. Refetoff, E. Van Cauter et al. Interconnection between circadian clocks and thyroid function. Nat. Rev. Endocrinol. 15(10), 590–600 (2019)CrossRefPubMedPubMedCentral
32.
33.
go back to reference D. Zhang, R.R. Jones, P. James et al. Associations between artificial light at night and risk for thyroid cancer: a large US cohort study. Cancer. 127(9), 1448–1458 (2021)CrossRefPubMed D. Zhang, R.R. Jones, P. James et al. Associations between artificial light at night and risk for thyroid cancer: a large US cohort study. Cancer. 127(9), 1448–1458 (2021)CrossRefPubMed
34.
go back to reference F. Di Cara, S. Savary, W.J. Kovacs et al. The peroxisome: an up-and-coming organelle in immunometabolism. Trends Cell Biol. 33(1), 70–86 (2023)CrossRefPubMed F. Di Cara, S. Savary, W.J. Kovacs et al. The peroxisome: an up-and-coming organelle in immunometabolism. Trends Cell Biol. 33(1), 70–86 (2023)CrossRefPubMed
35.
go back to reference E. Semikasev, B. Ahlemeyer, T. Acker et al. Rise and fall of peroxisomes during Alzheimer´s disease: a pilot study in human brains. Acta Neuropathol. Commun. 11(1), 80 (2023)CrossRefPubMedPubMedCentral E. Semikasev, B. Ahlemeyer, T. Acker et al. Rise and fall of peroxisomes during Alzheimer´s disease: a pilot study in human brains. Acta Neuropathol. Commun. 11(1), 80 (2023)CrossRefPubMedPubMedCentral
37.
go back to reference A. Rotte, S. Sahasranaman, N. Budha, Targeting TIGIT for immunotherapy of cancer: update on clinical development. Biomedicines. 9(9), 1277 (2021) A. Rotte, S. Sahasranaman, N. Budha, Targeting TIGIT for immunotherapy of cancer: update on clinical development. Biomedicines. 9(9), 1277 (2021)
38.
go back to reference S. Kurtulus, K. Sakuishi, S.F. Ngiow et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest 125(11), 4053–4062 (2015)CrossRefPubMedPubMedCentral S. Kurtulus, K. Sakuishi, S.F. Ngiow et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest 125(11), 4053–4062 (2015)CrossRefPubMedPubMedCentral
39.
go back to reference J. Niu, C. Maurice-Dror, D.H. Lee et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer(☆). Ann. Oncol. 33(2), 169–180 (2022)CrossRefPubMed J. Niu, C. Maurice-Dror, D.H. Lee et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer(☆). Ann. Oncol. 33(2), 169–180 (2022)CrossRefPubMed
Metadata
Title
Prediction of TNFRSF9 expression and molecular pathological features in thyroid cancer using machine learning to construct Pathomics models
Authors
Ying Liu
Junping Zhang
Shanshan Li
Wen Chen
Rongqian Wu
Zejin Hao
Jixiong Xu
Publication date
16-05-2024
Publisher
Springer US
Published in
Endocrine
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-024-03862-9

A quick guide to ECGs

Electrocardiography Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

Obesity Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more